Core One Labs Inc.: Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases

VANCOUVER, BC / ACCESSWIRE / January 24, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), in follow-up to its press release dated September 16

Related Keywords

Colombia ,United States ,Canada ,Toronto ,Ontario ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Vancouver ,British Columbia ,Canadian ,Medina Granada ,Robertew Hancock ,Christian Gri ,Boshi Gimpera ,Joel Shacker ,University Of Barcelona The Investigators ,Javeriana University Medical School ,Trademark Office ,University Of Toronto ,Canadian Securities Exchange ,Company Or Core ,Head Of Scientific Development ,University Of Barcelona ,Universitat De Barcelona The University Of ,Biosciences Inc ,Core One Labs Inc ,Akome Biotech Ltd ,Vocan Biotechnologies Inc ,Zone See Company ,Health Canada ,Core One Labs Inc View ,Core One Labs ,Akome Biotech ,Universitat De Barcelona ,Alzheimer Disease ,Ischemic Stroke ,Neuro Zone Srl ,Luniversidad Complutense ,United States Patent ,Santiago Ferro ,Core One ,Chief Medical Officer ,Chief Executive Officer ,Internal Medicine ,Infectious Diseases ,Chief Execute Officer ,Scientific Development ,Vocan Biotechnologies ,One Labs ,Awakened Biosciences Inc ,Disclaimer Statement ,Controlled Drugs ,Substances Act ,Core ,Labs ,Okome ,Signs ,Contract ,University ,Initiating ,Animal ,Model ,Studies ,Psychedelics ,Drug ,Development ,Combat ,Variety ,Neurological ,Diseases ,